Compounds. BSP shall have sole discretion to determine the clinical development program for the Compounds. This shall include the right to determine which, if any, Compound to enter into Clinical Trials, the design of the Clinical Trials, how to proceed in the Clinical Trials, the minimum or specific number of trials or Specimens to run, which countries to pursue, and whether and when to stop any Clinical Trial.
Appears in 2 contracts
Sources: Research Collaboration and License Agreement, Research Collaboration and License Agreement (Prometheus Laboratories Inc)